hat
Pwoblèm sa a soti nan lefèt ke medikaman sa a se yon agonist 5-HT2C minè 5-HT2C ki asosye sitou ak pèdi pwa, ke yo te apwouve pa FDA pou sa a ak lefèt Flibanserin a se yon minè te bay fanm pèsepsyon ke li ta lakòz yo jwenn pwa.
eng
The issue resulted from the fact that this drug is a minor 5-HT2C receptor 5-HT2C agonist is mainly associated with weight loss, having been approved by FDA for this and the fact the Flibanserin is a minor gave women the perception that it would cause them to gain weight.